🏢Companies
10 companiesAionics
Aionics
AI platform for accelerating battery and energy materials discovery. Electrolyte design AI for solid-state and lithium-ion batteries. Backed by Andreessen Horowitz. Series A funded.
Matterworks
Matterworks
AI-driven materials discovery startup using generative AI and high-throughput experiments. Focus on industrial and functional materials. Seed-stage backed by prominent climate-tech investors.
Atomwise
Atomwise
AI drug discovery company using AtomNet deep learning for virtual screening. 750 plus disease targets screened. Partnership with Eli Lilly and AbbVie. Raised 150M Series B.
DeepMind AlphaFold
DeepMind
Google DeepMind AlphaFold solved the protein folding problem. AlphaFold 3 covers all molecules. 200M plus protein structures in database. AlphaFold Server used by 1M plus researchers.
Recursion Pharmaceuticals
Recursion
Clinical-stage biotech combining AI and high-content imaging to discover new drugs. Partners with Roche and Bayer. NASDAQ RXRX with 140 plus active programs across oncology and rare diseases.
Schrodinger
Schrodinger
Computational drug discovery platform combining physics-based simulation and machine learning. FEP+ and Glide tools used by top 20 pharma companies. NASDAQ SDGR with 1B plus partnership deals.
DP Technology
DP Technology
Chinese AI for science company building Bohrium cloud platform and DeePMD force fields. Backed by Hillhouse and Sequoia China. Bridging AI and molecular dynamics for materials and drug discovery.
NVIDIA BioNeMo
NVIDIA BioNeMo
NVIDIA AI platform for drug discovery and biological research. BioNeMo framework for training and deploying biomolecular AI models. Powers molecular docking, protein design, and genomics workflows.
Xtalpi
Xtalpi
AI drug and materials discovery company using quantum physics and AI. Proprietary Forecaster platform for crystal structure prediction. Listed on HKEX 2024. Partners include Pfizer and J&J. HKEX 2228.
Insilico Medicine
Insilico Medicine
AI drug discovery company using generative AI PandaOmics and Chemistry42 to design novel drugs. First AI-designed drug candidate to enter Phase II clinical trials. Pre-IPO Hong Kong based.
📊Research Reports
View all →No reports yet for this sub-sector.
📰Latest News
View all →AI Sector Update: AI for Science platforms are accelerating drug discovery, materials science, and
Industry Wire
AI Sector Update: AI Agents are being deployed at scale across enterprise workflows, with autonomo
Industry Wire
AI Sector Update: Computer Vision applications are expanding into industrial inspection, autonomou
Industry Wire
AI Sector Update: AI Agents are being deployed at scale across enterprise workflows, with autonomo
AMORA Intelligence